Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy.
Doxorubicin-induced cardiomyopathy is not uncommon and may progress to end-stage heart failure. Treatment of this condition with heart transplantation, however, requires that the primary malignancy be deemed "cured." We present the case of a 55- year-old woman who had doxorubicin-induced cardiomyopathy and non-Hodgkin's lymphoma. The active status of her lymphoma precluded heart transplantation. She had end-stage heart failure and underwent the insertion of a left ventricular assist device as a destination therapy.
Simsir
Sinan A
SA
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.
Lin
Shu S
SS
Blue
Laura J
LJ
Gockerman
John P
JP
Russell
Stuart D
SD
Milano
Carmelo A
CA
D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000601:surgery; D004317:Doxorubicin / Q000009:adverse effects*; D005260:Female; D006333:Heart Failure / Q000139:chemically induced / Q000601:surgery*; D006353:Heart-Assist Devices; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008875:Middle Aged
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin